NCT00471081 - Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. | Biotech Hunter

Enrollment

385

Participants

Timeline

Start Date

July 5, 2007

Primary Completion Date

October 23, 2008

Study Completion Date

November 26, 2008

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL

Meningococcal vaccine GSK134612

One or 2 intramuscular injections.

Trial Locations (19)

16125

GSK Investigational Site, Greenville

16501

GSK Investigational Site, Erie

35205

GSK Investigational Site, Birmingham

35244

GSK Investigational Site, Birmingham

44718

GSK Investigational Site, Canton

72015

GSK Investigational Site, Benton

72205

GSK Investigational Site, Little Rock

79124

GSK Investigational Site, Amarillo

80033

GSK Investigational Site, Wheat Ridge

80122

GSK Investigational Site, Littleton

80226

GSK Investigational Site, Lakewood

80234

GSK Investigational Site, Littleton

GSK Investigational Site, Westminster

93637

GSK Investigational Site, Madera

94509

GSK Investigational Site, Antioch

94538

GSK Investigational Site, Fremont

94545

GSK Investigational Site, Hayward

95403

GSK Investigational Site, Santa Rosa

95688

GSK Investigational Site, Vacaville